New hope for tough cancers: trial tests Two-Drug attack on advanced sarcoma
NCT ID NCT07460986
Summary
This study is testing whether adding a new immunotherapy drug, bexmarilimab, to a standard chemotherapy (doxorubicin) is safe and more effective for people with metastatic soft-tissue sarcoma. The main goals are to find the safest dose of the new combination and to see if it can better control the cancer and help patients live longer without their disease getting worse. It is for adults with specific types of this advanced cancer who have not yet received certain prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA OF SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.